Written by the Nuvirox Research Team
Key points
- Mitochondrial dysfunction is well documented in multiple sclerosis and is thought to contribute to both neurodegeneration and MS-related fatigue.
- A clinical trial testing nicotinamide riboside specifically in progressive MS is actively underway (NCT05740722), but has not yet reported results.
- This is squarely a conversation to have with a neurologist, not a supplement decision to make independently.
Short answer: there's a real, active clinical trial testing this, but no completed efficacy data exists yet. If you or someone you love has MS, the honest state of the science is "being tested," not "shown to work."
Why would NAD+ matter for multiple sclerosis?
MS is an inflammatory, demyelinating disease of the central nervous system, and a substantial body of research shows mitochondrial dysfunction is present from early in the disease course through progressive stages. In the MS cortex, chronically activated immune cells (microglia) generate reactive oxygen and nitrogen species that damage neuronal mitochondria and mitochondrial DNA, impairing energy production. Because fatigue is one of the most disabling and common MS symptoms, and mitochondrial energy failure is a plausible contributor, NAD+ precursors — which support mitochondrial function broadly — are a logical research target.
What does the evidence actually show?
A registered clinical trial (ClinicalTrials.gov NCT05740722) is currently testing nicotinamide riboside at 1,000 mg daily against placebo in patients with progressive MS (secondary or primary progressive), randomized 1:1, assessing safety and efficacy for disability progression. As of this writing, this trial has not published completed results. Separately, brain-imaging research using MR spectroscopy has found metabolic abnormalities (elevated lactate, impaired post-exercise creatine response) in the brains of MS patients that correlate with fatigue, reinforcing that an energy-metabolism-based approach is mechanistically reasonable to test — but reasonable-to-test is different from proven.
Study snapshot: Nicotinamide riboside trial in progressive MS (ongoing)
| Registry | ClinicalTrials.gov NCT05740722 |
| Design | Randomized, double-blind, placebo-controlled |
| Dose | 1,000 mg NR daily vs. placebo |
| Population | Progressive MS (SPMS or PPMS), ages 18-65 |
| Status | Recruiting/ongoing; no completed results published yet |
The honest counterweight
It's worth being direct: as of today, there is no completed, published clinical trial showing that NAD+ precursor supplementation improves MS symptoms, fatigue, or disease progression. What exists is a strong mechanistic rationale and an active trial designed to test it — which is exactly the stage where it would be premature to treat this as an established benefit. MS disease-modifying therapies, which have transformed outcomes for many patients over the past two decades, have gone through exactly this kind of rigorous trial process; NAD+ precursors for MS have not yet completed that process.
When to see a doctor
Multiple sclerosis requires ongoing neurological care, and disease-modifying therapies are central to slowing disability progression — a decision that should never be made around a supplement instead of, or without discussing with, your neurology team. If you're interested in the ongoing NR trial, ask your neurologist whether you might be eligible to participate, which is a very different path from simply buying a supplement.
What's actually proven to help
FDA-approved disease-modifying therapies remain the evidence-backed foundation of MS treatment, chosen based on MS subtype and individual factors. For MS-related fatigue specifically, energy conservation strategies, structured exercise programs, and medications like amantadine or modafinil have trial support, alongside treating contributing factors like poor sleep or depression.
How does this compare to other neurodegenerative NAD+ research?
MS sits alongside Parkinson's disease as one of the more actively studied neurodegenerative conditions in current NAD+ precursor research, though the MS trial is considerably earlier-stage than the Parkinson's research program, which has already completed multiple phase I human trials. Both conditions share the same underlying rationale — mitochondrial dysfunction contributing to neurodegeneration — documented in our broader coverage of mitochondria supplements and which ingredients have genuine trial support for supporting mitochondrial function.
It's worth understanding why fatigue specifically is such a research priority in MS: unlike the visible disability progression that disease-modifying therapies target, MS-related fatigue often doesn't respond well to existing treatments and significantly affects quality of life independent of physical disability measures. That's part of why researchers are willing to test an NAD+ precursor's effect on disability progression broadly (as the ongoing trial does) rather than fatigue alone — a positive signal on either measure would represent meaningful progress. For related inflammatory considerations, see our page on NAD+ and inflammation.
For additional context on trial design: the ongoing NR trial in progressive MS specifically excludes patients using high-dose vitamin B3 supplementation, which is a useful reminder that researchers are being careful to isolate the effect of a controlled clinical dose from whatever supplements patients might already be taking — a good practice that also means results, whenever they're published, will be more interpretable than if patients' existing supplement use had been left uncontrolled.
If you're an MS patient interested in general NAD+ precursor supplementation for unrelated wellness goals while this research develops, it's especially important to discuss it with your neurologist given that some MS disease-modifying therapies affect liver metabolism and immune function in ways that could plausibly interact with any new supplement, even one without direct evidence of harm.
For readers tracking this research area over time, ClinicalTrials.gov listings are updated as trials progress and eventually post results, so checking the NCT05740722 listing periodically is a reliable way to follow this specific trial's progress directly from the source, rather than relying on secondhand summaries that may lag behind or misrepresent the actual findings once they're published.
In the meantime, the disease-modifying therapies and symptom-management approaches your neurology team already has access to remain the best-evidenced path forward, with this research representing a promising but still-unproven future direction rather than a current option.
Staying connected with an MS specialty center, rather than relying on general primary care alone, tends to give patients earlier access to emerging trial opportunities like this one as they open enrollment.
Frequently asked questions
Is there a real clinical trial testing NAD+ for MS?
Yes — nicotinamide riboside is being tested in a registered trial for progressive MS, but it hasn't reported completed results.
Should I take an NAD+ supplement for my MS symptoms in the meantime?
This is a conversation to have directly with your neurologist, who knows your full treatment picture and can advise on interactions with your current therapy.
Does mitochondrial dysfunction cause MS?
It's considered a contributor to the neurodegeneration and fatigue seen in MS, not the root autoimmune cause of the disease itself.
From Nuvirox
Why we formulated NAD+ Restore
To be direct: NAD+ Restore is a general wellness supplement, not a treatment for this condition, and it shouldn't be used as a substitute for medical care. If you're separately interested in cellular energy support once your care team is in the loop, here's what's in it.
- 500 mg Nicotinamide Riboside Chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials
- 150 mg trans-resveratrol (Japanese Knotweed) + 50 mg quercetin (Sophora japonica) — polyphenols studied alongside NAD+ pathways for cellular health support
- 10 mg galactomannans from fenugreek — to support absorption
- 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should
The bottom line: the mitochondrial-dysfunction rationale for testing NAD+ precursors in MS is genuinely solid science, and a real trial is underway — but "being tested" and "proven to help" are different claims, and MS management belongs with your neurology team.
References
- Nicotinamide Riboside Supplementation in Progressive Multiple Sclerosis. ClinicalTrials.gov NCT05740722.
- Mitochondrial dysfunction contributes to neurodegeneration in multiple sclerosis. Trends Mol Med. 2013.
- Metabolic Dysfunction Underlying Fatigue in Multiple Sclerosis. 2025 (preprint/bioRxiv).
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.